Next Generation News and Research

RSS

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia. The event marks the 50th anniversary of the discovery of the first genetic abnormality associated with cancer, and the first to lead to a targeted therapy for cancer.

25 Aug 2010

Bisphenol A chemical may shorten reproductive lifespan in women: Research

A study posted today (Wednesday, August 25) at the online site of the journal Biology of Reproduction reports that exposure of pregnant female mice to the endocrine-disrupting chemical bisphenol A may produce adverse reproductive consequences on gene expression in fetal ovaries as early as 12 hours after the mother has first been exposed to the chemical.

25 Aug 2010

U.S. DOE awards Dynasil 7 Phase-II SBIR grants totaling $6.2 million

Dynasil Corporation of America today announced that the U.S. Department of Energy (DOE) has approved seven of its Phase-II SBIR projects for awards, ranging from $750,000 to $1,000,000 each. The awards, totaling $6.2 million, are being made to its wholly owned subsidiary, Radiation Monitoring Devices, Inc, to develop its state of the art nuclear sensors and instruments.

25 Aug 2010

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

25 Aug 2010

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Kamada, Ltd., a biopharmaceutical company engaged in development, production and marketing of specialty life-saving therapeutics and Baxter International Inc., a global, diversified healthcare company announced today that they have entered into an exclusive distribution and manufacturing agreement for Kamada's liquid, ready to use, intravenous Alpha-1 Antitrypsin Product for the treatment of hereditary Alpha-1 Antitrypsin Deficiency approved by the USFDA on July 1st, 2010 for marketing under the trade name "Glassia™".

From Baxter International Inc. 25 Aug 2010

CHI teams with BioFortis to focus on personalized healthcare initiatives for community hospitals

Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.

25 Aug 2010

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

24 Aug 2010

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

Baxter International Inc. today announced a definitive agreement with Kamada Ltd. for exclusive commercial rights to GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid alpha1-proteinase inhibitor, in the United States, Australia, New Zealand and Canada.

From Baxter International Inc. 24 Aug 2010

Samplify receives second series of patent for medical imaging applications

Samplify Systems, Inc., a leading provider of signal-compression technology, semiconductors, and solutions, today announced that the Chinese Government has granted the company its second series of technology patents for medical imaging applications. These new patents come on the heels of the first series of patents that were granted earlier this month for wireless base station compression.

23 Aug 2010

Experts explore factors contributing to global nurse faculty migration

Twenty-one experts from 12 countries convened near Geneva, Switzerland, in late June to explore current patterns, types, and causal and contributing factors of global nurse faculty migration, a phenomenon where nursing faculty leave their country of origin to work elsewhere.

21 Aug 2010

Angeion partners with Data Innovations to create MedGraphics BreezeConnect software interface

Angeion Corporation today announced that it has partnered with Data Innovations to create MedGraphics BreezeConnect, a software interface that provides interfacing options in one comprehensive solution. BreezeConnect is currently available in the United States and is expected to launch internationally in September.

21 Aug 2010

Bavarian Nordic comments on Obama Administration's revised strategy for medical countermeasures

Bavarian Nordic A/S -- a leading industrial biotechnology company and long-term collaborator with the U.S. Government on the development of vaccines for the protection against biological threats, today commented on the Obama Administration's revised strategy for development, procurement and stockpiling of medical countermeasures.

20 Aug 2010

Statoil ASA launches new ear plug to alleviate noise-induced hearing impairment

Some 600 cases of noise-induced hearing impairment are reported by the Norwegian petroleum industry every year. A new, intelligent earplug is now set to alleviate the problem.

20 Aug 2010

USPTO rules out Oculir's claim on noninvasive glucose measuring device patent

The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.

20 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Varian Medical Systems, Inc. will showcase the company's new Gated RapidArc technology on its Trilogy® machine with advanced motion management capabilities at the 2010 CHINA-HOSPEQ exhibition being held in Beijing August 19-21 by China's Ministry of Health. Varian, the world's leading manufacturer of medical technology for treating cancer and a premier supplier of X-ray imaging technology, will also exhibit its software for planning and for managing radiation therapy treatments.

18 Aug 2010

Medtronic to acquire Osteotech for $6.50 per share

Medtronic Inc.,and Osteotech, Inc.,today announced that the companies have signed a definitive agreement under which Medtronic will acquire Osteotech for $6.50 per share in cash for each share of Osteotech common stock. The total value of the transaction is expected to be approximately $123 million.

18 Aug 2010

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany's first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix's long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

17 Aug 2010

IVAX Diagnostics second quarter 2010 operating expenses decrease 11.9%

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended June 30, 2010.

17 Aug 2010

Next Generation News and Research

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

Bisphenol A chemical may shorten reproductive lifespan in women: Research

U.S. DOE awards Dynasil 7 Phase-II SBIR grants totaling $6.2 million

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

CHI teams with BioFortis to focus on personalized healthcare initiatives for community hospitals

3SBio and Isotechnika enter strategic agreement for voclosporin in China

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

Samplify receives second series of patent for medical imaging applications

Experts explore factors contributing to global nurse faculty migration

Angeion partners with Data Innovations to create MedGraphics BreezeConnect software interface

Bavarian Nordic comments on Obama Administration's revised strategy for medical countermeasures

Statoil ASA launches new ear plug to alleviate noise-induced hearing impairment

USPTO rules out Oculir's claim on noninvasive glucose measuring device patent

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Medtronic to acquire Osteotech for $6.50 per share

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

IVAX Diagnostics second quarter 2010 operating expenses decrease 11.9%

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News